<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology - Haas, DM - 2019 | Cochrane Library</title> <meta content="Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology - Haas, DM - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003511.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology - Haas, DM - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003511.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003511.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology" name="citation_title"/> <meta content="David M Haas" name="citation_author"/> <meta content="Indiana University School of Medicine" name="citation_author_institution"/> <meta content="dahaas@iupui.edu" name="citation_author_email"/> <meta content="Taylor J Hathaway" name="citation_author"/> <meta content="Indiana University School of Medicine" name="citation_author_institution"/> <meta content="Patrick S Ramsey" name="citation_author"/> <meta content="Uniformed Services University of Health Sciences" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003511.pub5" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/11/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003511.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003511.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003511.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abortion, Habitual [*etiology, prevention &amp; control]; Abortion, Spontaneous [prevention &amp; control]; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth [prevention &amp; control]; Progesterone [deficiency, *metabolism]; Progestins [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003511.pub5&amp;doi=10.1002/14651858.CD003511.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003511\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003511\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","th","ko","ms","ja","fa","de","zh_HANS","zh_HANT","pt"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003511.pub5",title:"Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology",firstPublishedDate:"Nov 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003511.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003511.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003511.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003511.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003511.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003511.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003511.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003511.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003511.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003511.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14074 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003511.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-sec-0082"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/appendices#CD003511-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/table_n/CD003511StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/table_n/CD003511StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information#CD003511-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>David M Haas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information#CD003511-cr-0003">Taylor J Hathaway</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information#CD003511-cr-0004">Patrick S Ramsey</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information/en#CD003511-sec-0140">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 November 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003511.pub5">https://doi.org/10.1002/14651858.CD003511.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003511-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003511-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003511-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003511-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003511-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003511-abs-0017">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD003511-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003511-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003511-abs-0001" lang="en"> <section id="CD003511-sec-0001"> <h3 class="title" id="CD003511-sec-0001">Background</h3> <p>Progesterone, a female sex hormone, is known to induce secretory changes in the lining of the uterus essential for successful implantation of a fertilized egg. It has been suggested that a causative factor in many cases of miscarriage may be inadequate secretion of progesterone. Therefore, clinicians use progestogens (drugs that interact with the progesterone receptors), beginning in the first trimester of pregnancy, in an attempt to prevent spontaneous miscarriage. This is an update of a review, last published in 2013. </p> <p>Since publication of the 2018 update of this review, we have been advised that the Ismail 2017 study is currently the subject of an investigation by the Journal of Maternal‐Fetal &amp; Neonatal Medicine. We have now moved this study from 'included studies' to 'Characteristics of studies awaiting classification' until the outcome of the investigation is known. </p> </section> <section id="CD003511-sec-0002"> <h3 class="title" id="CD003511-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of progestogens as a preventative therapy against recurrent miscarriage. </p> </section> <section id="CD003511-sec-0003"> <h3 class="title" id="CD003511-sec-0003">Search methods</h3> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (6 July 2017) and reference lists from relevant articles, attempting to contact trial authors where necessary, and contacted experts in the field for unpublished works. </p> </section> <section id="CD003511-sec-0004"> <h3 class="title" id="CD003511-sec-0004">Selection criteria</h3> <p>Randomized or quasi‐randomized controlled trials comparing progestogens with placebo or no treatment given in an effort to prevent miscarriage. </p> </section> <section id="CD003511-sec-0005"> <h3 class="title" id="CD003511-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. Two reviewers assessed the quality of the evidence using the GRADE approach. </p> </section> <section id="CD003511-sec-0006"> <h3 class="title" id="CD003511-sec-0006">Main results</h3> <p>Twelve trials (1,856 women) met the inclusion criteria. Eight of the included trials compared treatment with placebo and the remaining four trials compared progestogen administration with no treatment. The trials were a mix of multicenter and single‐center trials, conducted in India, Jordan, UK and USA. In five trials women had had three or more consecutive miscarriages and in seven trials women had suffered two or more consecutive miscarriages. Routes, dosage and duration of progestogen treatment varied across the trials. The majority of trials were at low risk of bias for most domains. Ten trials (1684 women) contributed data to the analyses. </p> <p>The meta‐analysis of all women, suggests that there may be a reduction in the number of miscarriages for women given progestogen supplementation compared to placebo/controls (average risk ratio (RR) 0.73, 95% confidence interval (CI) 0.54 to 1.00, 10 trials, 1684 women, moderate‐quality evidence). A subgroup analysis comparing placebo‐controlled versus non‐placebo‐controlled trials, trials of women with three or more prior miscarriages compared to women with two or more miscarriages and different routes of administration showed no clear differences between subgroups for miscarriage. </p> <p>None of the trials reported on any secondary maternal outcomes, including severity of morning sickness, thromboembolic events, depression, admission to a special care unit, or subsequent fertility. </p> <p>There was probably a slight benefit for women receiving progestogen seen in the outcome of live birth rate (RR 1.07, 95% CI 1.00 to 1.13, 6 trials, 1411 women, moderate‐quality evidence). We are uncertain about the effect on the rate of preterm birth because the evidence is very low‐quality (RR 1.13, 95% CI 0.53 to 2.41, 4 trials, 256 women, very low‐quality evidence). No clear differences were seen for women receiving progestogen for the other secondary outcomes including neonatal death, fetal genital abnormalities or stillbirth. There may be little or no difference in the rate of low birthweight and trials did not report on the secondary child outcomes of teratogenic effects or admission to a special care unit. </p> </section> <section id="CD003511-sec-0007"> <h3 class="title" id="CD003511-sec-0007">Authors' conclusions</h3> <p>For women with unexplained recurrent miscarriages, supplementation with progestogen therapy may reduce the rate of miscarriage in subsequent pregnancies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003511-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003511-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003511-abs-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003511-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003511-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003511-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003511-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003511-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003511-abs-0018">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD003511-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003511-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003511-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003511-abs-0006" lang="en"> <h3>Progestogen for preventing miscarriage</h3> <p><b>What is the issue?</b> </p> <p>Early pregnancy loss, also known as miscarriage, generally occurs in the first trimester. For some women and their partners, miscarriages can happen several times, also known as recurrent miscarriages. While there are sometimes causes for miscarriages that are found, often no clear reasons can be found. The hormone called progesterone prepares the womb (uterus) to receive and support the newly fertilized egg during the early part of pregnancy. It has been suggested that some women who miscarry may not make enough progesterone in the early part of pregnancy. Supplementing these women with medications that act like progesterone (these are called progestogens) has been suggested as a possible way to prevent recurrent miscarriage. </p> <p>Since publication of the 2018 update of this review, we have been advised that one study (by Ismail 2017) is currently the subject of an investigation by the Journal of Maternal‐Fetal &amp; Neonatal Medicine. We have now moved this study from 'included studies' to 'Characteristics of studies awaiting classification' until the outcome of the investigation is known. </p> <p><b>Why is this important?</b> </p> <p>Having miscarriages can be both physically and emotionally difficult for women and their partners. Finding a therapy to help reduce recurrent miscarriages could help them avoid a miscarriage and have a live baby. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for evidence on 6 July 2017 and identified a total of 13 trials that enrolled a total of 2556 women with a history of recurrent miscarriages. These trials found that giving progestogen medication to women with recurrent miscarriages early in their pregnancy may help lower the rates of miscarriage in that pregnancy from 27.5% to 20.1%. We believe that these findings are based on evidence of only moderate quality, so we cannot be certain about the results. We did not find that giving the progestogen medication by mouth, as a shot (injection), or in the vagina, was any better than any of the other ways. We also found that the trials showed that giving progestogen to women with prior recurrent miscarriages made the chances of having a live baby in the current pregnancy slightly higher. We are uncertain about the effect on the rate of preterm birth because the evidence is very low‐quality. We did not find evidence of improvement in other outcomes such as newborn death, stillbirth, low birthweight, or newborn birth defects for women given progestogens. </p> <p><b>What does this mean?</b> </p> <p>We found evidence from randomized controlled trials that giving progestogen medication may prevent miscarriage for women with recurrent previous miscarriages. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003511-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003511-sec-0130"></div> <h3 class="title" id="CD003511-sec-0131">Implications for practice</h3> <section id="CD003511-sec-0131"> <p>For women with unexplained recurrent miscarriages, supplementation with progestogen therapy may reduce the rate of miscarriage in subsequent pregnancies. </p> </section> <h3 class="title" id="CD003511-sec-0132">Implications for research</h3> <section id="CD003511-sec-0132"> <p>As noted, the included trials utilized many different treatment protocols including when the progestogen was started and how long into gestation it was continued. Coming to a more standard treatment protocol for study in future trials, along with establishing a uniform core outcome set, would be beneficial for future trials. This would also aid in translation into practice. Including patient‐centered outcomes such as progestogen tolerability would also be appropriate in future trials. More data comparing the different routes or types of progestogens may also be beneficial. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003511-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003511-sec-0036"></div> <div class="table" id="CD003511-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Progestogen compared to placebo/no treatment for preventing miscarriage in women with recurrent miscarriage of unclear etiology</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Progestogen compared to placebo/no treatment for preventing miscarriage in women with recurrent miscarriage of unclear etiology</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent miscarriage of unclear etiology<br/> <b>Setting:</b> mix of multicenter and single‐center trials based in Egypt, India, Jordan, UK and USA </p> <p><b>Intervention:</b> progestogen<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Miscarriage</b> (all trials) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>average RR 0.73<br/> (0.54 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1684<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000<br/> (149 to 275) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (1.00 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1411<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>701 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000<br/> (701 to 793) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Preterm birth</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.53 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>256<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/> (40 to 180) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded (1) level for serious limitations in study design due to some of the studies being at high or unclear risk for selection bias. </p> <p><sup>2</sup> We downgraded (2) levels for very serious limitations in imprecision due to small number of events, small sample size and wide CI crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003511-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003511-sec-0037"></div> <section id="CD003511-sec-0038"> <h3 class="title" id="CD003511-sec-0038">Description of the condition</h3> <p>The term miscarriage refers to the loss of a pregnancy prior to the fetus being viable. This can be defined as reaching 20 or 24 weeks' gestation depending on the source of the data. Vaginal bleeding during the first 20 weeks of pregnancy, with or without pain, is known as threatened miscarriage. This can present with anything from spots of blood to potentially fatal shock (<a href="./references#CD003511-bbs2-0063" title="McBrideWZ . Spontaneous abortion. American Family Physician1991;43:175‐82. ">McBride 1991</a>). Once dilation of the cervix has begun, miscarriage is inevitable (<a href="./references#CD003511-bbs2-0062" title="LedeR , DuleyL . Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD002857.pub2] ">Lede 2005</a>). </p> <p>Ten per cent to 15% of all clinically recognized pregnancies end in miscarriage (<a href="./references#CD003511-bbs2-0067" title="ReganL , BraudePB , TrembathPR . Influences of past reproductive performance on risk of spontaneous abortion. BMJ1989;299:541‐5. ">Regan 1989</a>), with 1% to 2% of couples suffering recurrent early losses (traditionally defined as three or more spontaneous miscarriages; <a href="./references#CD003511-bbs2-0049" title="CoulamCB . Epidemiology of recurrent spontaneous abortion. American Journal of Reproductive Immunology1991;26:23‐7. ">Coulam 1991</a>). It is thought, however, that the true incidence of early spontaneous miscarriage may be much higher (<a href="./references#CD003511-bbs2-0055" title="GrudzinskasJG . Endocrinocolgical and metabolical assessment of early pregnancy. In: ChamberlainG editor(s). Tumbull's Obstetrics. London: Pearson Professional Ltd, 1995. ">Grudzinskas 1995</a>; <a href="./references#CD003511-bbs2-0059" title="HowiePG . Abortion and ectopic pregnancy. In: WhitfieldCR editor(s). Dewhurst's Textbook of Obstetrics and Gynaecology for Postgraduates. Oxford: Blackwell Science Ltd, 1995. ">Howie 1995</a>; <a href="./references#CD003511-bbs2-0074" title="SimpsonJL . Fetal wastage. In: GabeSG , SimpsonJL editor(s). Obstetrics. Normal and Problem Pregnancies. New York: Churchill Livingstone Inc, 1991. ">Simpson 1991</a>). Miscarriage is an important cause of morbidity and mortality, especially in low‐income countries (<a href="./references#CD003511-bbs2-0065" title="NeilsonJP , HickeyM , VazquezJ . Medical treatment for early fetal death (less than 24 weeks). Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD002253.pub3] ">Neilson 2006</a>). </p> <p>It has been estimated that, in over half of miscarriages, a chromosomal abnormality is present (<a href="./references#CD003511-bbs2-0047" title="BurgoynePS , HollandK , StephensR . Incidence of numerical chromosome anomalies in human pregnancy estimation from induced and spontaneous abortion data. Human Reproduction1991;6(4):555‐65. ">Burgoyne 1991</a>; <a href="./references#CD003511-bbs2-0076" title="SzaboI , SzilagyiA . Management of threatened abortion. Early Pregnancy1996;2(4):233‐40. ">Szabo 1996</a>). Other risk factors include maternal age greater than 35 years, multiple pregnancies, uterine malformations, polycystic ovaries, autoimmune factors (such as phospholipid antibodies, lupus anticoagulant and cardiolipin antibodies), genetic disorders, poorly controlled diabetes, and having had two or more miscarriages (<a href="./references#CD003511-bbs2-0062" title="LedeR , DuleyL . Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD002857.pub2] ">Lede 2005</a>). Many of these conditions can lead to recurrent miscarriage, traditionally defined as three or more miscarriages (<a href="./references#CD003511-bbs2-0069" title="Royal College of Obstetricians and Gynaecologists. The management of recurrent miscarriage. www.rcog.org.uk/guidelines/recurrent.html(accessed 2001). ">Royal 2001</a>). For many women and their partners, a cause of recurrent miscarriage may never be found. With the development of ultrasound and improvements in pregnancy testing, pregnancies can be diagnosed earlier, even if destined for early miscarriage. In the past, these may not have been detected. Thus, the number of women reporting early pregnancy loss may increase. </p> <p>The occurrence of a miscarriage may induce significant emotional distress in both partners. Initial emotional numbness and denial, anxiety, shock, sense of loss, sadness, emptiness, anger, inadequacy, blame and jealousy, depression, sleep disturbance, social withdrawal, anger and marital disturbance have all been described as emotional responses to pregnancy loss (<a href="./references#CD003511-bbs2-0044" title="AtkinLC , ArcelusM , FernandezA , TolbertK . La Psicologia en el Ambito Perinatal. Mexico D.F: INPER, 1988. ">Atkin 1998</a>; <a href="./references#CD003511-bbs2-0052" title="DyregroveA , MathiesonSB . Stillbirth, neonatal death and SIDS: parental reactions. Scandanavian Journal of Psychology1987;28:104‐14. ">Dyregrove 1987</a>; <a href="./references#CD003511-bbs2-0077" title="VanceJC , FosterWJ , NajmanJM , Embelton , ThearleMJ , HogdenFM . Early parental responses to sudden infant death, stillbirth or neonatal death. Medical Journal of Australia1991;155(5):292‐7. ">Vance 1991</a>; <a href="./references#CD003511-bbs2-0079" title="WoodsJR , EspositoJL . Pregnancy Loss: Medical Therapeutics and Practical Considerations. Baltimore: Williams and Wilkins, 1987. ">Woods 1987</a>). </p> </section> <section id="CD003511-sec-0039"> <h3 class="title" id="CD003511-sec-0039">Description of the intervention</h3> <p>Progesterone and other progestogens can be given to women orally, vaginally, intramuscularly, or by other routes. Supplementing a pregnancy with progestin often begins early in the first trimester after a positive pregnancy test is obtained (under 14 weeks' gestation) and can continue throughout the first trimester and beyond. The therapeutic intervention can be with natural progesterone or with any other progestogen that interacts with and stimulates the progesterone receptor. </p> </section> <section id="CD003511-sec-0040"> <h3 class="title" id="CD003511-sec-0040">How the intervention might work</h3> <p>Progesterone, a female sex hormone, is known to induce secretory changes in the lining of the uterus essential for successful implantation of a fertilized egg. It is secreted chiefly by the corpus luteum, a group of cells formed in the ovary after the follicle ruptures during the release of the egg. It has been suggested that a causative factor in many cases of miscarriage may be inadequate secretion of progesterone during the luteal phase of the menstrual cycle and in the early weeks of pregnancy. Therefore, clinicians use progestogens, beginning in the first trimester of pregnancy, in an attempt to prevent spontaneous miscarriage. Their use is particularly common with assisted reproductive technologies. For women with recurrent miscarriages, whose evaluation has not yielded a specific cause, the presumed diagnosis of a deficiency in progesterone as a cause of the miscarriages has led to women begin given supplemental progestins to help 'support' the pregnancy. </p> <p>A review of pregnancy rates following hormonal treatments for various conditions concluded that the benefits of therapy are uncertain (<a href="./references#CD003511-bbs2-0060" title="KaramadianLM , GrimesDA . Luteal phase deficiency. Effect of treatment on pregnancy rates. American Journal of Obstetrics and Gynecology1992;167:1391‐8. ">Karamadian 1992</a>). A 1989 meta‐analysis of six trials concluded that exogenous progesterone supplementation after conception does not improve pregnancy outcomes (<a href="./references#CD003511-bbs2-0053" title="GoldsteinP , BerrierJ , RosenS , SacksHS , ChalmersTC . A meta‐analysis of randomised control trials of progestational agents in pregnancy. British Journal of Obstetrics and Gynaecology1989;96:265‐74. ">Goldstein 1989</a>; <a href="./references#CD003511-bbs2-0067" title="ReganL , BraudePB , TrembathPR . Influences of past reproductive performance on risk of spontaneous abortion. BMJ1989;299:541‐5. ">Regan 1989</a>). It was concluded that low levels of progesterone in early pregnancy reflected an already failed pregnancy (<a href="./references#CD003511-bbs2-0069" title="Royal College of Obstetricians and Gynaecologists. The management of recurrent miscarriage. www.rcog.org.uk/guidelines/recurrent.html(accessed 2001). ">Royal 2001</a>). </p> <p>Concerns have been raised that the use of progestogens, with their uterine‐relaxant properties, in women with fertilized defective ova may cause a delay in spontaneous abortion. Reports also suggest a potential association between intrauterine exposure to progesterone containing drugs in the first trimester of pregnancy and genital abnormalities in male and female fetuses. The risk of hypospadias (deformities of the penis or urethra, or both), 5 to 8 per 1000 male births in the general population, may be increased with exposure to these drugs (<a href="./references#CD003511-bbs2-0046" title="BriggsGG , FreemanRK , YaffeSJ . Drugs in Pregnancy and Lactation. 9th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2011. ">Briggs 2011</a>). However, some trials do not report increased risk with exposure to these drugs and progesterone supplementation is commonly utilized in assisted reproduction settings. There are insufficient data to quantify the risk to exposed female fetuses. Due to some of these reports and the fact that the urogenital groove is fused by 16 weeks, some have recommended that progesterone‐containing drugs be avoided in the first 16 weeks of pregnancy (<a href="./references#CD003511-bbs2-0046" title="BriggsGG , FreemanRK , YaffeSJ . Drugs in Pregnancy and Lactation. 9th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2011. ">Briggs 2011</a>). </p> </section> <section id="CD003511-sec-0041"> <h3 class="title" id="CD003511-sec-0041">Why it is important to do this review</h3> <p>Several Cochrane Reviews have been initiated to investigate different interventions for the prevention of miscarriage (<a href="./references#CD003511-bbs2-0043" title="AlfirevicZ , StampalijaT , RobertsD , JorgensenAL . Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008991.pub2] ">Alfirevic 2012</a>; <a href="./references#CD003511-bbs2-0045" title="BamigboyeAA , MorrisJ . Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD004353] ">Bamigboye 2003</a>; <a href="./references#CD003511-bbs2-0062" title="LedeR , DuleyL . Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD002857.pub2] ">Lede 2005</a>; <a href="./references#CD003511-bbs2-0064" title="MorleyLC , SimpsonN , TangT . Human chorionic gonadotrophin (hCG) for preventing miscarriage. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD008611.pub2] ">Morley 2013</a>; <a href="./references#CD003511-bbs2-0066" title="PorterTF , LaCoursiereY , ScottJR . Immunotherapy for recurrent miscarriage. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD000112.pub2] ">Porter 2006</a>; <a href="./references#CD003511-bbs2-0070" title="RumboldA , MiddletonP , PanN , CrowtherCA . Vitamin supplementation for preventing miscarriage. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004073.pub3] ">Rumbold 2011</a>). The aim of this updated review is to study all available data to determine the efficacy and safety of administering prophylactic progesterone in an attempt to prevent pregnancy loss in the population of women with recurrent miscarriages. There is a separate Cochrane Review on the use of progestogens for treating women with threatened miscarriage (<a href="./references#CD003511-bbs2-0078" title="WahabiHA , FayedAA , EsmaeilSA , BahkaliKH . Progestogen for treating threatened miscarriage. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD005943.pub5] ">Wahabi 2018</a>). This is an update of a review last published in 2013 (<a href="./references#CD003511-bbs2-0081" title="HaasDM , RamseyPS . Progestogen for preventing miscarriage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD003511.pub3] ">Haas 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003511-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003511-sec-0042"></div> <p>To assess the efficacy and safety of progestogens as a preventative therapy against recurrent miscarriage. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003511-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003511-sec-0043"></div> <section id="CD003511-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003511-sec-0045"> <h4 class="title">Types of studies</h4> <p>Randomized or quasi‐randomized trials comparing progestogens with placebo or no treatment, given for the prevention of miscarriage, were eligible for inclusion. Cluster‐randomized trials were also eligible for inclusion, but cross‐over design trials were not eligible. </p> </section> <section id="CD003511-sec-0046"> <h4 class="title">Types of participants</h4> <p>Women who were diagnosed with recurrent miscarriages (usually of unknown origin) and who began treatment with progestins in the first trimester of pregnancy. We placed no restriction on the age of participants or past obstetric history otherwise. Where specified, we limited the analysis to singleton pregnancies. We excluded women achieving pregnancy by in‐vitro fertilization. </p> </section> <section id="CD003511-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Progestogen therapy, either natural or synthetic, given prophylactically to prevent recurrent miscarriage (i.e. loss during the first 20 weeks of pregnancy) versus placebo therapy or no therapy, regardless of dose, mode of administration or treatment duration. We considered trials pertaining to administration of progestogens starting before pregnancy if treatment continued after pregnancy was confirmed. </p> </section> <section id="CD003511-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD003511-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003511-list-0001"> <li> <p>Miscarriage ‐ defined by trial authors but typically as pregnancy loss less than 20 weeks' gestation </p> </li> </ul> </p> </section> <section id="CD003511-sec-0050"> <h5 class="title">Secondary outcomes</h5> <section id="CD003511-sec-0051"> <h6 class="title">Mother</h6> <p> <ul id="CD003511-list-0002"> <li> <p>Maternal adverse events (from progestogen)</p> </li> <li> <p>Severity of 'morning sickness' ‐ intensified headache, nausea, breast tenderness</p> </li> <li> <p>Reported thromboembolic events</p> </li> <li> <p>Depression</p> </li> <li> <p>Admission to special care unit</p> </li> <li> <p>Subsequent fertility</p> </li> </ul> </p> </section> <section id="CD003511-sec-0052"> <h6 class="title">Child</h6> <p> <ul id="CD003511-list-0003"> <li> <p>Live birth rate (defined as number of live births in entire study population)</p> </li> <li> <p>Preterm birth (&lt; 37 weeks' gestation)</p> </li> <li> <p>Neonatal death</p> </li> <li> <p>Fetal genital abnormalities</p> </li> <li> <p>Stillbirth (fetal loss after 20 weeks' gestation in women with a viable pregnancy after 20 weeks) </p> </li> <li> <p>Low birthweight less than 2500 g</p> </li> <li> <p>Teratogenic effects (impairing normal fetal development)</p> </li> <li> <p>Admission to special care unit</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD003511-sec-0053"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD003511-sec-0054"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (6 July 2017) </p> <p>The Register is a database containing over 25,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this <a href="https://pregnancy.cochrane.org/pregnancy-and-childbirth-groups-trials-register" target="_blank">link</a>. </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD003511-list-0004"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD003511-bbs1-0001" title="">Included studies</a>; <a href="./references#CD003511-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD003511-bbs1-0004" title="">Ongoing studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (6 July 2017) for unpublished, planned and ongoing trial reports using the terms listed in <a href="./appendices#CD003511-sec-0136">Appendix 1</a>. </p> </section> <section id="CD003511-sec-0055"> <h4 class="title">Searching other resources</h4> <p>We searched the citation lists of relevant publications, review articles, abstracts of scientific meetings and included studies for both published and unpublished works but did not find any additional references. </p> <p>We contacted experts in the field for unpublished works. None were revealed to us.</p> <p>We obtained all reports that described (or may have described) randomized controlled trials of prophylactic progestogen to prevent pregnancy loss for women with recurrent pregnancy loss. We did not apply any language or date restrictions and attempted to make to contact with trial authors when we required additional information. </p> </section> </section> <section id="CD003511-sec-0056"> <h3 class="title" id="CD003511-sec-0056">Data collection and analysis</h3> <p>For methods used in the previous version of this review, see <a href="./references#CD003511-bbs2-0081" title="HaasDM , RamseyPS . Progestogen for preventing miscarriage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD003511.pub3] ">Haas 2013</a>. </p> <p>For this update, we used the following methods, based on a standard template used by Cochrane Pregnancy and Childbirth, to assess the reports that we identified as a result of the updated search. </p> <section id="CD003511-sec-0057"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed for inclusion all the potential trials that we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third person. </p> <p>Additionally, as this Cochrane Review's focus had shifted specifically to women with recurrent miscarriage, we re‐evaluated the prior included trials and excluded ones that did not report on women with recurrent miscarriages. </p> </section> <section id="CD003511-sec-0058"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data. For eligible trials, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third person. We entered data into Review Manager 5 software (<a href="./references#CD003511-bbs2-0068" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) and checked for accuracy. </p> <p>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD003511-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003511-bbs2-0058" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available fromwww.training.cochrane.org/handbook. ">Higgins 2017</a><i>).</i> We resolved any disagreement by discussion or by involving a third assessor. </p> <section id="CD003511-sec-0060"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>For each included study we assessed the method as being at:</p> <p> <ul id="CD003511-list-0005"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003511-sec-0061"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>For each included study we described the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as being at:</p> <p> <ul id="CD003511-list-0006"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003511-sec-0062"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>For each included study we described the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding was unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as being at:</p> <p> <ul id="CD003511-list-0007"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD003511-sec-0063"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>For each included study we described the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as being at:</p> <p> <ul id="CD003511-list-0008"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003511-sec-0064"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>For each included study, and for each outcome or class of outcomes, we described the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re‐include missing data in the analyses that we undertook. </p> <p>We assessed methods as being at:</p> <p> <ul id="CD003511-list-0009"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003511-sec-0065"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>For each included study we described how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as being at:</p> <p> <ul id="CD003511-list-0010"> <li> <p>low risk of bias (where it was clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s prespecified outcomes were reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD003511-sec-0066"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>For each included study we described any important concerns we had about other possible sources of bias. </p> </section> <section id="CD003511-sec-0067"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003511-bbs2-0058" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available fromwww.training.cochrane.org/handbook. ">Higgins 2017</a>). With reference to (1) to (6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it was likely to have an impact on the findings. In future updates, we will explore the impact of the level of bias through undertaking sensitivity analyses (<a href="#CD003511-sec-0081">Sensitivity analysis</a>). </p> </section> <section id="CD003511-sec-0068"> <h5 class="title">Assessment of the quality of the evidence using the GRADE approach</h5> <p>For this update, we assessed the quality of the evidence using the GRADE approach, as outlined in the GRADE Handbook in order to assess the quality of the body of evidence relating to the outcome of miscarriage for the main comparisons of progestogen versus placebo/no treatment (<a href="./references#CD003511-bbs2-0073" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Available from gdt.gradepro.org/app/handbook/handbook.html. ">Schünemann 2013</a>). We assessed the following outcomes using GRADE: </p> <p> <ul id="CD003511-list-0011"> <li> <p>miscarriage;</p> </li> <li> <p>live birth rate;</p> </li> <li> <p>preterm birth.</p> </li> </ul> </p> <p>We used the GRADEpro Guideline Development Tool (<a href="./references#CD003511-bbs2-0054" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed August 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>), to import data from Review Manager 5 (<a href="./references#CD003511-bbs2-0068" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), in order to create 'Summary of findings' tables. We produced a summary of the intervention effect and a measure of quality for the above outcome using the GRADE approach (<a href="./references#CD003511-bbs2-0073" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Available from gdt.gradepro.org/app/handbook/handbook.html. ">Schünemann 2013</a>). The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> <section id="CD003511-sec-0069"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003511-sec-0070"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratio (RR) with 95% confidence intervals (CIs).  </p> </section> <section id="CD003511-sec-0071"> <h5 class="title">Continuous data</h5> <p>None of our outcomes have continuous data. If future updates add continuous data, we will use the mean difference if outcomes are measured in the same way between trials. We will use the standardized mean difference to combine trials that measure the same outcome, but use different methods.   </p> </section> </section> <section id="CD003511-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <section id="CD003511-sec-0073"> <h5 class="title">Cluster‐randomized trials</h5> <p>We did not include cluster‐randomized trials in this Cochrane Review. In future updates, if we identify any high‐quality cluster‐randomized trials, we will consider including them in the analyses along with individually randomized trials. We will adjust their sample sizes using the methods described in section 16.3.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, using an estimate of the intracluster correlation co‐efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population (<a href="./references#CD003511-bbs2-0057" title="HigginsJP , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomized trials and individually randomized trials, we plan to synthesize the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomization unit is considered to be unlikely. </p> <p>We will also acknowledge heterogeneity in the randomization unit and perform a sensitivity analysis to investigate the effects of the randomization unit. </p> </section> <section id="CD003511-sec-0074"> <h5 class="title">Cross‐over trials</h5> <p>Cross‐over trials are not included as they are inappropriate to the question.</p> </section> <section id="CD003511-sec-0075"> <h5 class="title">Other unit of analysis issues</h5> <p>If we identify and include trials with more than two treatment groups, we will assess the most appropriate way to include the data. This may be by combining groups to create a pair‐wise comparison or to select the most appropriate pair of interventions and exclude the others. We did not identify any such trials. </p> </section> </section> <section id="CD003511-sec-0076"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. In future updates we will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, that is, we attempted to include all participants randomized to each group in the analyses, and all participants were analyzed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomized minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD003511-sec-0077"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² (<a href="./references#CD003511-bbs2-0056" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐560. ">Higgins 2003</a>), and Chi² statistics (<a href="./references#CD003511-bbs2-0050" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). We regarded heterogeneity as substantial if an I² statistic was greater than 30% and either the T² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.  </p> </section> <section id="CD003511-sec-0078"> <h4 class="title">Assessment of reporting biases</h4> <p>As there were more than 10 studies in the meta‐analysis, we investigated reporting biases (such as publication bias) using funnel plots, see <a href="#CD003511-fig-0001">Figure 1</a>. We assessed funnel plot asymmetry visually. As asymmetry was not suggested by a visual assessment, we did not perform exploratory analyses to investigate it further (<a href="./references#CD003511-bbs2-0075" title="SterneJA , EggerM , MoherD , BoutronI (editors) . Chapter10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Sterne 2017</a>). </p> <div class="figure" id="CD003511-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 1. Progestogen versus placebo/no treatment, outcome 1.1 Miscarriage (all trials)" data-id="CD003511-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 1. Progestogen versus placebo/no treatment, outcome 1.1 Miscarriage (all trials) </p> </div> </div> </div> </section> <section id="CD003511-sec-0079"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 software (<a href="./references#CD003511-bbs2-0068" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: that is, where trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we detected substantial statistical heterogeneity, we planned to use random‐effects meta‐analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. Where we used random‐effects meta‐analysis, we treated the random‐effects summary as the average of range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we planned not to combine trials. If we used random‐effects analyses, we presented the results as the average treatment effect with 95% CIs, and the estimates of  Tau² and I². </p> </section> <section id="CD003511-sec-0080"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted planned subgroup analyses for the following subgroups:</p> <p> <ul id="CD003511-list-0012"> <li> <p>placebo‐controlled trials only versus trials not having placebo control;</p> </li> <li> <p>women with at least three previous consecutive miscarriages versus women with at least two prior miscarriages; </p> </li> <li> <p>route of administration of progestogen: oral, intramuscular or vaginal versus placebo.</p> </li> </ul> </p> <p>We used only the primary outcome in subgroup analysis: miscarriage.</p> <p>We assessed subgroup differences by interaction tests available within Review Manager 5 (<a href="./references#CD003511-bbs2-0068" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We reported the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value. </p> </section> <section id="CD003511-sec-0081"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analysis to explore the effect of risk of bias. This involved analysis of trials based on low risk of bias in order to assess for any substantive difference to the overall results. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003511-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003511-sec-0082"></div> <section id="CD003511-sec-0083"> <h3 class="title">Description of studies</h3> <section id="CD003511-sec-0084"> <h4 class="title">Results of the search</h4> <p>See: <a href="#CD003511-fig-0002">Figure 2</a> for full details of the updated search process. </p> <div class="figure" id="CD003511-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD003511-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>The July 2017 search retrieved 14 new trial reports to assess, plus there were three previously ongoing trials to reassess. One of the previously ongoing trials had been published and we included it (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>). We included three other, newly identified trials (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>). Three of the reports were ongoing trials listed in trials registries (<a href="./references#CD003511-bbs2-0039" title="IRCT2013100114853N1 . Effect of concomitant administration of vaginal progesterone and vitamin D3 in the treatment of unexplained recurrent abortion in pregnant women. en.search.irct.ir/view/15255 (first received 30 October 2013). ">IRCT2013100114853N1</a>; <a href="./references#CD003511-bbs2-0038" title="ACTRN12611000401954 . Does using progesterone reduce the miscarriage rate in high risk pregnancies? Pregnancy Maintenance Trial (PMTrial). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000401954 18 April 2011. ">ACTRN12611000401954</a>; <a href="./references#CD003511-bbs2-0041" title="NCT02706470 . A randomized, controlled trial of cyclosporin a for women with unexplained recurrent miscarriage. clinicaltrials.gov/ct2/show/record/NCT02706470 (first received 12 March 2016). ">NCT02706470</a>). Attempts to contact the authors were not fruitful. One study (<a href="./references#CD003511-bbs2-0037" title="IsmailA , NasrA , AminA , Al‐InanyH . Peri‐conceptional progesterone treatment in women with unexplained recurrent miscarriage, a randomized double‐blind controlled trial. Human Reproduction2015;30:i194, abstract no: P‐167. IsmailAM , AbbasAM , AliMK , AminAF . Peri‐conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double‐blind placebo‐controlled trial. Journal of Maternal‐Fetal &amp; Neonatal Medicine 23 January 2017 [Epub ahead of print]. NCT01670929 . Pr‐conceptional progesterone for unexplained recurrent miscarriage. clinicaltrials.gov/ct2/show/record/NCT01670929 (first received 17 August 2012). ">Ismail 2017</a>) was previously included in this update but has now been moved to studies awaiting classification pending the outcome of a formal investigation ‐ see .'Studies awaiting classification' below. </p> <p>In this update the scope changed to include specifically women with recurrent pregnancy loss. Four trials included in previous versions of the review were therefore excluded from this update as the populations dealt with women having threatened miscarriage symptoms (<a href="./references#CD003511-bbs2-0013" title="BerleP , BudenzM , MichaelisJ . Is hormonal therapy still justified in imminent abortion?. Zeitschrift fur Geburtshilfe und Perinatologie1980;184:353‐8. ">Berle 1980</a>; <a href="./references#CD003511-bbs2-0023" title="GerhardI , GwinnerB , Eggert‐KruseW , RunnebaumB . Double‐blind controlled trial of progesterone substitution in threatened abortion. Biological Research in Pregnancy and Perinatology1987;8:26‐34. ">Gerhard 1987</a>; <a href="./references#CD003511-bbs2-0026" title="MollerK , FuchsF . Double blind controlled trial of 6‐methyl‐17‐acetoxyprogesterone in threatened abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1042‐4. ">Moller 1965</a>; <a href="./references#CD003511-bbs2-0035" title="TognoniG , FerrarioL , InzalacoM , CrosignaniP . Progestogens in threatened abortion. Lancet1980;2(8206):1242‐3. ">Tognoni 1980</a>). One previously included trial was excluded as it only enrolled women getting a genetic amniocentesis (<a href="./references#CD003511-bbs2-0020" title="CorradoF , DugoC , CannataM , DiBartoloM , ScilipotiA , StellaN . A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2002;100(2):196‐8. ">Corrado 2002</a>), and one previously included trial was excluded as it only enrolled women receiving in‐vitro fertilization or other reproductive assistance (<a href="./references#CD003511-bbs2-0028" title="Nyboe AndersonA , Popovic‐TodorovicB , SchmidtK , LoftA , LindhardA , HojgaardA , et al. Progesterone supplement during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17(2):357‐61. ">Nyboe Anderson 2002</a>). </p> <p>This resulted in a total of 12 included trials and five <a href="./references#CD003511-bbs1-0004" title="">Ongoing studies</a>. </p> </section> <section id="CD003511-sec-0085"> <h4 class="title">Included studies</h4> <section id="CD003511-sec-0086"> <h5 class="title">Trial design characteristics</h5> <section id="CD003511-sec-0087"> <h6 class="title">Interventions</h6> <section id="CD003511-sec-0088"> <p><b>Route of administration</b></p> <p>Seven trials administered treatment orally (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>); three administered treatment intramuscularly (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>); one used vaginal micronized progesterone (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>); and one used progestogen pellets inserted into the gluteal muscle (<a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). </p> </section> <section id="CD003511-sec-0089"> <p><b>Dosage and type of progestogen</b></p> <p>Of the trials that administered treatment orally, one study used a dose of 10 mg/day medroxyprogesterone (<a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>), one study used a twice‐daily dose of cyclopentyl enol ether of progesterone (Enol Luteovis), (<a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>), while three used 10 mg of oral dydrogesterone either twice daily (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>) or three times daily (<a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>). One trial gave participants 20 mg of oral dydrogesterone daily (<a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>). One trial used 200 mg oral micronized progesterone twice daily (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>). </p> <p>In the three trials that administered treatment intramuscularly, two trials used a dose of 500 mg of hydroxyprogesterone caproate (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>), while the third study used a staggered dose, also of hydroxyprogesterone caproate, of between 250 to 500 mg depending on week of gestation (<a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). </p> <p>The remaining two trials (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>) delivered treatment via 400 mg micronized progesterone vaginally, 400 mg progesterone pessaries, and six times 25 mg progesterone pellets inserted within the gluteal muscle, respectively. </p> </section> <section id="CD003511-sec-0090"> <p><b>Duration of treatment</b></p> <p>There was a wide variation in treatment duration between trials. One study continued treatment until the 24th week of pregnancy (<a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>); and one study continued treatment until miscarriage or until 36 weeks' gestation (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>). Several trials continued treatment until the 12th week of gestation (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>). One trial continued therapy to 16 weeks' gestation (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>) and one continued up to 20 weeks' gestation (<a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>). In the remaining four trials treatment duration was either not stated or unclear (<a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>), although <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a> stated that they hospitalized participants starting at under 10 weeks' gestation until they were 18 weeks' gestation but was unclear how long the treatment lasted. </p> </section> <section id="CD003511-sec-0091"> <p><b>Placebo/control</b></p> <p>Eight of the included trials compared treatment with placebo (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). The remaining four trials compared progestogen administration with no treatment (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). </p> </section> <section id="CD003511-sec-0092"> <p><b>Contribution to meta‐analysis</b></p> <p>One study included women with recurrent pregnancy loss among all recruited women but did not report outcomes for this group separately, so did not contribute to the meta‐analysis (<a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>) and one study compared oral or vaginal progestogen to a control group of women without a history of recurrent pregnancy loss (<a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>) and thus did not have an adequate control group so did not contribute data to the meta‐analysis. All other included trials contributed data to at least one comparison. </p> </section> </section> </section> <section id="CD003511-sec-0093"> <h5 class="title">Baseline characteristics of participants</h5> <section id="CD003511-sec-0094"> <h6 class="title">Number of prior miscarriages</h6> <p>Five trials required women to have had three or more consecutive miscarriages (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>), and seven trials required women to have suffered two or more consecutive miscarriages (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). In addition, one study (<a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>) required women to have cervical mucus ferning as evidence of "significant hormonal imbalance". </p> <p>Only one study excluded women who had experienced a live birth (<a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>). </p> </section> </section> <section id="CD003511-sec-0095"> <h5 class="title">Gestation</h5> <p>Most other trials recruited women in the first trimester of pregnancy with various cut‐offs of gestational age. One trial accepted women to the 20th gestational week (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>). </p> </section> <section id="CD003511-sec-0096"> <h5 class="title">Studied outcomes for trials contributing to meta‐analysis</h5> <p> <ul id="CD003511-list-0013"> <li> <p>Miscarriage: 10 trials included miscarriage as an outcome.</p> </li> <li> <p>Live birth rate: specifically reported by two trials (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). For other trials, extrapolated from data if they presented birth data and reported individual or group outcomes and either reported a number of stillbirths or did not note any stillbirths </p> </li> <li> <p>Preterm birth: four trials reported preterm delivery (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). </p> </li> <li> <p>Intrauterine fetal death/still birth: two trials reported intrauterine fetal death/still birth as an outcome (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). </p> </li> <li> <p>Fetal genital abnormalities/teratogenic effects, fetal deformities: three trials (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>) reported fetal or genital abnormalities, or both, as an outcome. </p> </li> <li> <p>Neonatal death: three trials contributed data for neonatal death (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). </p> </li> <li> <p>Low birthweight less than 2500 g: several trials reported birthweight as an outcome but only one categorized it as less than 2500 g (<a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>). </p> </li> <li> <p>Severity of morning sickness, intensified headache, nausea, or breast tenderness: no trials reported on these as separate outcomes. </p> </li> <li> <p>Thromboembolic events: no trials reported thromboembolic rates as an outcome.</p> </li> <li> <p>Admission to special care unit: no trials reported admission to special care units as an outcome. </p> </li> <li> <p>Maternal depression: no trials reported maternal depression as an outcome.</p> </li> <li> <p>Subsequent fertility: no trials reported subsequent fertility as an outcome.</p> </li> </ul> </p> </section> <section id="CD003511-sec-0097"> <h5 class="title">Support/sponsorship</h5> <p>Six trials reported what appeared to be support or sponsorship from pharmaceutical companies (<a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). Two reports were funded by governmental grants from India (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>), and one by governmental grants from the UK (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>). One study specified that no support was obtained (<a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>). Two trials did not mention any support (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>). (See <a href="./references#CD003511-sec-0147" title="">Characteristics of included studies</a>). </p> <p>All of the trials either declared no competing interests (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>) or did not state if any interests existed (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). One study mentioned specifically that one of the authors was grateful to a provider of the study drug but did not clarify the relationship (<a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). </p> </section> <section id="CD003511-sec-0098"> <h5 class="title">Number of centers</h5> <p>Some of the trials were multicenter (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>), the rest were either single‐center trials (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>) or the number of centers was unclear (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>). </p> </section> </section> <section id="CD003511-sec-0099"> <h4 class="title">Excluded studies</h4> <p>On obtaining the full papers, we found that five trials were not randomized controlled trials (<a href="./references#CD003511-bbs2-0015" title="CheckJ , WuC‐H , AdelsonH . Decreased abortion in HMG‐induced pregnancies. International Journal of Fertility1985;30(3):45‐7. ">Check 1985</a>; <a href="./references#CD003511-bbs2-0016" title="CheckJ , ChaseJ , NowrooziK , WuC , AdelsonH . Progesterone therapy to decrease first‐trimester spontaneous abortions in previous aborters. International Journal of Fertility1987;32(3):192‐9. ">Check 1987a</a>; <a href="./references#CD003511-bbs2-0021" title="DayaS , WardS , BurrowsE . Progesterone profiles in luteal phase defect cycles and outcome of progesteron treatment in patients with recurrent spontaneous abortion. American Journal of Obstetrics and Gynecology1988;158(2):225‐32. ">Daya 1988</a>; <a href="./references#CD003511-bbs2-0030" title="RockJ , Colston WentzA , ColeK , KimballA , ZacurH , EarlyS , et al. Fetal malformations following progesterone therapy during pregnancy: a preliminary report. Fertility and Sterility1985;44(1):17‐9. ">Rock 1985</a>; <a href="./references#CD003511-bbs2-0032" title="SidelnikovaVM , DemidovaEM , BorisovaIF , DondukovaTM , AbsavaGI , KorkhovVV . The use of acetomepegrenol in the therapy of threatened abortion. Akusherstvo i Ginekologiia1990;66(9):37‐40. ">Sidelnikova 1990</a>), and it was unclear if there was any randomization in another (<a href="./references#CD003511-bbs2-0017" title="CheckJ , ChaseJ , WuC , AdelsonH , TeichmanM , RankinA . The efficacy of progesterone in achieving successful pregnancy: prophylactic use during luteal phase in anovulatory women. International Journal of Fertility1987;32(2):135‐8. ">Check 1987b</a>). Five trials were not concerned with investigating the effects of progestogen for miscarriage, but were concerned with investigating other effects of progesterone, such as on preterm birth or other outcomes (<a href="./references#CD003511-bbs2-0014" title="BrennerW , HendricksC . Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation labour. American Journal of Obstetrics and Gynecology1962;83(8):1094‐8. ">Brenner 1962</a>; <a href="./references#CD003511-bbs2-0024" title="JohnsonJ , AustinK , JonesG , DavisG , KingT . Efficacy of 17 alpha‐hydroxyprogesterone caproate on the prevention of premature labour. New England Journal of Medicine1975;298(14):675‐80. ">Johnson 1975</a>; <a href="./references#CD003511-bbs2-0025" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , et al. Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD003511-bbs2-0034" title="SondergaardF , OttesenB , DetlefsenGU , SchierupL , PedersonSC , LebechPE . Progesterone treatment of cases of threatened pre‐term delivery in women with a low level of plasma progesterone. Contraception, Fertilite, Sexualite1985;13(12):1227‐31. ">Sondergaard 1985</a>; <a href="./references#CD003511-bbs2-0036" title="TurnerSJ , MizockGB , FeldmanGL . Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy. American Journal of Obstetrics and Gynecology1966;95:222‐7. ">Turner 1966</a>), three used progestogen combination therapy rather than progestogen alone (<a href="./references#CD003511-bbs2-0018" title="CheckJH , TarquiniP , GandyP , LauerC . A randomized study comparing the efficacy of reducing the spontaneous abortion rate following lymphocyte immunotherapy and progesterone treatment vs progesterone alone in primary habitual aborters. Gynecologic and Obstetric Investigation1995;39:257‐61. ">Check 1995</a>; <a href="./references#CD003511-bbs2-0029" title="PrietlG , DiedrichK , Van derVenHH , LuckhausJ , KrebsD . The effect of 17alpha‐hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial. Human Reproduction1992;7(1):1‐5. ">Prietl 1992</a>; <a href="./references#CD003511-bbs2-0031" title="ShuJ , MiaoP , WangRJ . Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody‐positive early recurrent spontaneous abortion. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi//Chinese Journal of Integrated Traditional and Western Medicine2002;22(6):414‐6. ">Shu 2002</a>), one did not administer progestogen during pregnancy (<a href="./references#CD003511-bbs2-0019" title="CliffordK , RaiR , WatsonH , FranksS , ReganL . Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. BMJ1996;312:1508‐11. ">Clifford 1996</a>), and one compared two types of progestogen rather than progestogen with no treatment or a placebo group (<a href="./references#CD003511-bbs2-0033" title="SmitzJ , DevroeyP , FaguerB , BourgainC , CamusM , VanSteirteghemAC . Randomized prospective trial comparing supplementation of the luteal phase and of early pregnancy by natural progesterone given by intramuscular or vaginal administration. Revue Francaise de Gynecologie et d Obstetrique1992;87:507‐16. ">Smitz 1992</a>). One trial was excluded due to using progestogen therapy after 20 weeks' gestation to prevent preterm labor (<a href="./references#CD003511-bbs2-0027" title="NormanJE . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT). National Research Register. www.nrr.nhs.uk (accessed 6 July 2006). ">Norman 2006</a>). We excluded one additional trial due to being terminated before data collection was complete (<a href="./references#CD003511-bbs2-0022" title="FuchsF , OlsenP . An attempted double‐blind controlled trial of progesterone therapy in habitual abortion. Ugeskrift for Laeger1966;128:1461‐2. ">Fuchs 1966</a>). </p> <p>As stated above, for this update we excluded six previously included trials; four for treating threatened miscarriage (<a href="./references#CD003511-bbs2-0013" title="BerleP , BudenzM , MichaelisJ . Is hormonal therapy still justified in imminent abortion?. Zeitschrift fur Geburtshilfe und Perinatologie1980;184:353‐8. ">Berle 1980</a>; <a href="./references#CD003511-bbs2-0023" title="GerhardI , GwinnerB , Eggert‐KruseW , RunnebaumB . Double‐blind controlled trial of progesterone substitution in threatened abortion. Biological Research in Pregnancy and Perinatology1987;8:26‐34. ">Gerhard 1987</a>; <a href="./references#CD003511-bbs2-0026" title="MollerK , FuchsF . Double blind controlled trial of 6‐methyl‐17‐acetoxyprogesterone in threatened abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1042‐4. ">Moller 1965</a>; <a href="./references#CD003511-bbs2-0035" title="TognoniG , FerrarioL , InzalacoM , CrosignaniP . Progestogens in threatened abortion. Lancet1980;2(8206):1242‐3. ">Tognoni 1980</a>), and two for ineligible patient populations (<a href="./references#CD003511-bbs2-0020" title="CorradoF , DugoC , CannataM , DiBartoloM , ScilipotiA , StellaN . A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2002;100(2):196‐8. ">Corrado 2002</a>; <a href="./references#CD003511-bbs2-0028" title="Nyboe AndersonA , Popovic‐TodorovicB , SchmidtK , LoftA , LindhardA , HojgaardA , et al. Progesterone supplement during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17(2):357‐61. ">Nyboe Anderson 2002</a>). See <a href="./references#CD003511-sec-0148" title="">Characteristics of excluded studies</a> for more details. </p> <section id="CD003511-sec-0100"> <h5 class="title">Studies awaiting classification</h5> <p>Since publication of the 2018 update of this review, we have been advised that the <a href="./references#CD003511-bbs2-0037" title="IsmailA , NasrA , AminA , Al‐InanyH . Peri‐conceptional progesterone treatment in women with unexplained recurrent miscarriage, a randomized double‐blind controlled trial. Human Reproduction2015;30:i194, abstract no: P‐167. IsmailAM , AbbasAM , AliMK , AminAF . Peri‐conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double‐blind placebo‐controlled trial. Journal of Maternal‐Fetal &amp; Neonatal Medicine 23 January 2017 [Epub ahead of print]. NCT01670929 . Pr‐conceptional progesterone for unexplained recurrent miscarriage. clinicaltrials.gov/ct2/show/record/NCT01670929 (first received 17 August 2012). ">Ismail 2017</a> study is currently the subject of an investigation by the Journal of Maternal‐Fetal &amp; Neonatal Medicine. We have now moved this study from 'included studies' to 'studies awaiting classification' until the outcome of the investigation is known. </p> </section> </section> </section> <section id="CD003511-sec-0101"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD003511-fig-0003">Figure 3</a>; <a href="#CD003511-fig-0004">Figure 4</a> for a summary of risk of bias in included trials. </p> <div class="figure" id="CD003511-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD003511-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD003511-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003511-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD003511-sec-0102"> <h4 class="title">Allocation</h4> <p>Of the 12 trials that met the inclusion criteria, four had low risk of bias for random sequence generation. Three of the trials reported computer‐generated or other adequate methods of randomization (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>), and one used a random table produced by a statistician (<a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>). We found high risk of bias for two trials: one used alternation (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>), and one randomized by day of the week (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>). The risk of bias for random sequence generation was unclear for five other trials (<a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). In one study (<a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>), two centers took part. One center allocated by alternation, while the paper stated that the other used "randomization". However, the method of randomization was not stated and thus risk of bias is unclear. </p> <p>Regarding allocation concealment, of the 12 trials that met the inclusion criteria, we assessed five as low risk of bias. These trials used sequentially numbered ampules provided by a central source or the pharmaceutical company (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>); or sequentially numbered, sealed envelopes (<a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>). One study used sequentially numbered bottles, and the code was not broken until the end of the trial (<a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>). </p> <p>Three trials used clearly inadequate methods of allocation concealment, based on the day of the week or alternating A/B groups (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>); while the allocation in the remaining four trials was unclear (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). </p> </section> <section id="CD003511-sec-0103"> <h4 class="title">Blinding</h4> <p>Some trials blinded participants and providers but the majority of trials did not report on blinding of participants, providers, or outcome assessors. However, because the outcomes of miscarriage, live birth, etc. are unlikely to be influenced by knowledge of assignment group, per the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003511-bbs2-0058" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available fromwww.training.cochrane.org/handbook. ">Higgins 2017</a>), we assessed these also as low risk of bias, even when blinding was not explicitly stated. </p> <p>Eight trials used double‐blinding, where both the participant and treating provider do not know the allocation (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>; <a href="./references#CD003511-bbs2-0010" title="ReijndersFJ , ThomasCM , DoesburgWH , RollandR , EskesTK . Endocrine effects of 17 alpha‐hydroxyprogesterone caproate during early pregnancy: a double‐blind clinical trial. British Journal of Obstetrics and Gynaecology1988;95:462‐8. ">Reijnders 1988</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). One study used single‐blinding by keeping study investigators and sonologists unaware of the type of protocol used, but double‐blinding was not possible due to differing drug delivery methods (<a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>). The remaining three trials did not mention efforts at blinding but as the outcomes were unlikely to be influenced by blinding efforts, we assessed all as low risk of bias (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). </p> <p>Few trials stated if outcome assessors specifically were blinded. However, some stated that "study personnel" of some type were blinded (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). One stated that the randomization was unknown until the study was complete, thus highly likely that the outcome assessors were blinded (<a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>). The remainder did not clearly state that outcome assessors were blinded but it is unlikely that knowledge of assignment would influence outcomes being assessed and so these were assessed as being at low risk of bias. </p> </section> <section id="CD003511-sec-0104"> <h4 class="title">Incomplete outcome data</h4> <p>Most trials had low rates of attrition and accounted for participants well.</p> <p>One study reported a large number of dropouts (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>). Fifty‐six women were randomized but 26 women were excluded from the analysis: 16 were found not to be pregnant after they had been randomized, and 10 failed to return for injections. </p> </section> <section id="CD003511-sec-0105"> <h4 class="title">Selective reporting</h4> <p>The majority of trials reported on all planned outcomes relevant to this review.</p> </section> <section id="CD003511-sec-0106"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a> was only reported as an abstract of results located in a trials registry. As a full report was unavailable, it is unclear if there are other potential sources of bias. <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a> reported that a large group of the women were still pregnant and did not have final outcomes so we rated it as unclear risk of other bias, as there could be outcome differences at the time of delivery that were not reported. We assessed all the other trials as low risk of other potential sources of bias. </p> <section id="CD003511-sec-0107"> <h5 class="title">Publication bias</h5> <p>The funnel plot of study size and effect size did not visually suggest evidence of publication bias (<a href="#CD003511-fig-0001">Figure 1</a>). </p> <p>See <a href="./references#CD003511-sec-0147" title="">Characteristics of included studies</a> tables for individual details. </p> </section> </section> </section> <section id="CD003511-sec-0108"> <h3 class="title" id="CD003511-sec-0108">Effects of interventions</h3> <p>See: <a href="./full#CD003511-tbl-0001"><b>Summary of findings for the main comparison</b> Progestogen compared to placebo/no treatment for preventing miscarriage in women with recurrent miscarriage of unclear etiology</a> </p> <p>Twelve trials (1,856 women) met the inclusion criteria. Ten trials (1684 women) contributed data to the analyses. </p> <section id="CD003511-sec-0109"> <h4 class="title">Progestogen versus placebo/no treatment</h4> <section id="CD003511-sec-0110"> <h5 class="title">Primary outcomes</h5> <section id="CD003511-sec-0111"> <h6 class="title">Miscarriage</h6> <p>The meta‐analysis of the 10 included trials (1684 women) suggests that progestogen supplementation may reduce the miscarriage rate compared to placebo/control women (27.5% versus 20.1%, average risk ratio (average RR) 0.73, 95% confidence interval (CI) 0.54 to 1.00; Tau² = 0.08; Chi² = 14.53, df = 9 (P = 0.10); I² = 38%; moderate‐quality evidence; <a href="./references#CD003511-fig-0005" title="">Analysis 1.1</a>, <a href="./full#CD003511-tbl-0001">summary of findings Table for the main comparison</a>). This is based on moderate‐quality evidence with evidence being downgraded for limitations in study design. </p> <p>A sensitivity analysis eliminating the four trials at potentially higher risk of bias (having one or more areas assessed as potentially high risk of bias: <a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>) lessened the certainty of this effect (average RR 0.86, 95% CI 0.60 to 1.24). </p> </section> <section id="CD003511-sec-0112"> <h6 class="title">Trials with placebo controls</h6> <p>We carried out a subgroup analysis comparing trials that did use a placebo control and those that did not use a placebo (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). There was no strong evidence of a subgroup difference as indicated by the subgroup interaction test (test for subgroup differences: Chi² = 1.68, df = 1 (P = 0.19), I² = 40.6%). Both of these subgroups demonstrated that progestogen may reduce miscarriage rates (trials with placebo controls: average RR 0.82, 95% CI 0.58 to 1.16, 7 trials, 1381 women; trials without placebo controls: average RR 0.55, 95% CI 0.34 to 0.90, 3 trials, 303 women; <a href="./references#CD003511-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD003511-sec-0113"> <h6 class="title">Women with a history of three or more consecutive miscarriages</h6> <p>Five trials enrolled only women who had suffered three or more consecutive miscarriages (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0004" title="CTRI/2013/02/003406 . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent spontaneous miscarriage. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5847 (first received 18 February 2013). ChakravartyBN , GaneshA , ChowdhuriK , ShyamT , GhoshS , ChattopadhyayR . Assessment of endometrial vascularity following dydrogesterone and micronized progesterone administration in idiopathic recurrent miscarriage‐a preliminary study. Human Reproduction2012;27(Suppl 2):P089. GhoshS , ChattopadhyayR , GoswamiS , ChaudhuryK , ChakravartyB , GaneshA . Assessment of sub‐endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. Journal of Obstetrics &amp; Gynaecology Research2014;40(7):1871‐6. ">Ghosh 2014</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>). The rest of the trials enrolled women with two or more prior miscarriages or did not specify. The two largest trials (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>) enrolled women with three or more prior miscarriages. There was no evidence of subgroup differences in these groups of trials in their effects for the two populations (test for subgroup differences: Chi² = 2.08, df = 1 (P = 0.15), I² = 51.9%). The meta‐analysis showed a probable reduction in miscarriage rates for women with a history of three or more miscarriages who were given progestogen supplementation (average RR 0.59, 95% CI 0.34 to 1.01, 4 trials, 1334 women; <a href="./references#CD003511-fig-0007" title="">Analysis 1.3</a>). Because of a clinical trend toward evaluating women with only two prior miscarriages for causes, the subgroup analysis also analyzed women with at least two prior miscarriages. Progestogens probably make little or no difference in miscarriage rates for women with at least two or more miscarriages, although some of these women had more than two miscarriages prior to enrolment (average RR 0.98, 95% CI 0.64 to 1.52, 5 trials, 290 women; <a href="./references#CD003511-fig-0007" title="">Analysis 1.3</a>). Thus it is not possible to discern the impact of progestogen on women who only have two prior miscarriages. </p> </section> <section id="CD003511-sec-0114"> <h6 class="title">Route of administration of progestogen</h6> <p>There was no evidence of a subgroup difference based on the route of administration of the progestogen as indicated by the subgroup interaction test (test for subgroup differences: Chi² = 2.66, df = 2 (P = 0.27), I² = 24.7%). Six trials compared oral progestogen with placebo/no treatment and contributed to the meta‐analysis (<a href="./references#CD003511-bbs2-0001" title="CTRI/2016/09/007278 . Role of inflammatory markers in recurrent pregnancy loss and effect of oral micronized therapy on these cases. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14740 (first received 16 September 2016). ">Agarwal 2016</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0006" title="KlopperA , MacNaughtonM . Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth1965;72:1022‐8. ">Klopper 1965</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>). The meta‐analysis showed that there was probably little or no difference in miscarriage rates with oral progestogen supplementation compared to women who received a placebo or no treatment, although rates were lower with progestogens (average RR 0.66, 95% CI 0.39 to 1.13, 6 trials, 665 women; <a href="./references#CD003511-fig-0008" title="">Analysis 1.4</a>). </p> <p>Two trials compared intramuscular progestogen with placebo/no treatment (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0011" title="ShearmanR , GarrettW . Double‐blind study of effect of 17‐hydroxyprogesterone caproate on abortion rate. British Medical Journal1963;1:292‐5. ShearmanRP . Hormonal treatment of habitual abortion. In: UK editor(s). In: Progress In Infertility. Kistner RW (ed). Shearman 1963. London: J &amp; A Churchill, 1968:767‐77. ">Shearman 1963</a>). The meta‐analysis showed no clear difference in miscarriages between the progestogen and placebo group (average RR 0.63, 95% CI 0.30 to 1.30, 2 trials, 80 women; <a href="./references#CD003511-fig-0008" title="">Analysis 1.4</a>). </p> <p>Only one trial compared vaginally‐administered progestogen with placebo/no treatment (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>). There was probably little or no difference between the two groups with respect to the incidence of recurrent miscarriage (average RR 0.96, 95% CI 0.79 to 1.17, 1 trial, 826 women; <a href="./references#CD003511-fig-0008" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD003511-sec-0115"> <h5 class="title">Secondary outcomes</h5> <section id="CD003511-sec-0116"> <h6 class="title">Live birth rate</h6> <p>Two trials specifically reported live birth rate (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>), and we were able to extrapolate the live birth rate from the results given in a further four trials (<a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0009" title="MacDonaldRR , GouldenR , OakeyRE . Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics &amp; Gynecology1972;40(3):394‐402. ">MacDonald 1972</a>). The evidence suggests that live birth rates may be increased for women receiving progestogen supplementation compared to controls (RR 1.07, 95% CI 1.00 to 1.13, 6 trials, 1411 women; moderate‐quality evidence; <a href="./references#CD003511-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD003511-sec-0117"> <h6 class="title">Preterm birth</h6> <p>Four trials reported an incidence of premature birth (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0005" title="GoldzieherJW . Double‐blind trial of a progestin in habitual abortion. JAMA1964;188(7):651‐4. ">Goldzieher 1964</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). We are uncertain about the effect on the rate of preterm birth because the quality of this evidence is very low‐quality (RR 1.13, 95% CI 0.53 to 2.41, 4 trials, 256 women, very low‐quality evidence; <a href="./references#CD003511-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD003511-sec-0118"> <h6 class="title">Neonatal death</h6> <p>Three trials reported neonatal death as an outcome (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). There were few events in these trials and there probably is little or no difference between women receiving progestogen and controls (RR 1.74, 95% CI 0.36 to 8.46, 3 trials, 724 women; <a href="./references#CD003511-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD003511-sec-0119"> <h6 class="title">Fetal genital abnormalities</h6> <p>Three trials reported fetal genital abnormalities or virilization as an outcome (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>). Two trials reported no incidence of fetal abnormalities (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>; <a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>). One study reported a single case of fetal genital abnormality in both groups (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>). There were no differences in fetal genital anomalies (RR 1.04, 95% CI 0.07 to 16.50; 3 trials, 665 women; <a href="./references#CD003511-fig-0012" title="">Analysis 1.8</a>). One study reported two anomalies in the progestogen group (neural tube defect and non‐immune hydrops) and one case of multiple anomalies in the control group in a baby with Down's syndrome (<a href="./references#CD003511-bbs2-0003" title="ElZibdehM . Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric2002;5(Suppl 1):136. ElZibdehM . Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility1998;70(3 Suppl 1):S77‐S78. El‐ZibdehMY . Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry &amp; Molecular Biology2005;97(5):431‐4. ">El‐Zibdeh 2005</a>). No genital anomalies were noted in that study. </p> </section> <section id="CD003511-sec-0120"> <h6 class="title">Stillbirth</h6> <p>Two trials reported rates of stillbirth (<a href="./references#CD003511-bbs2-0002" title="CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine2015;373(22):2141‐8. CoomarasamyA , WilliamsH , TruchanowiczE , SeedPT , SmallR , QuenbyS , et al. PROMISE: first‐trimester progesterone therapy in women with a history of unexplained recurrent miscarriages ‐ a randomised, double‐blind, placebo‐controlled, international multicentre trial and economic evaluation. Health Technology Assessment2016;20(41):7‐91. ISRCTN92644181 . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). controlled‐trials.com/ISRCTN92644181 (first received 17 March 2009). ">Coomarasamy 2015</a>; <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a>). <a href="./references#CD003511-bbs2-0012" title="SwyerGI , DaleyD . Progesterone implantation in habitual abortion. British Medical Journal1953;1:1073‐86. ">Swyer 1953</a> did not have any cases of stillbirth. There appears to be little or no difference in stillbirth rates (RR 0.53, 95% CI 0.05 to 5.79, 2 trials, 644 women; <a href="./references#CD003511-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD003511-sec-0121"> <h6 class="title">Low birthweight (less than 2500 g)</h6> <p>One study reported low birthweight by this definition (<a href="./references#CD003511-bbs2-0007" title="KumarA , BegumN , PrasadS , AggarwalS , SharmaS . Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double‐blind, randomized, parallel, placebo‐controlled trial. Fertility and Sterility2014;102(5):1357‐63.e3. ">Kumar 2014</a>). There may be little or no difference in the rate of low birthweight babies (RR 0.67, 95% CI 0.36 to 1.26, 1 trial, 348 women; <a href="./references#CD003511-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD003511-sec-0122"> <h6 class="title">Maternal adverse events</h6> <p>One study listed maternal adverse effects as outcomes (<a href="./references#CD003511-bbs2-0008" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery1964;72:30‐6. ">Le Vine 1964</a>) but did not note any events. </p> </section> </section> <section id="CD003511-sec-0123"> <h5 class="title">Other secondary outcomes</h5> <p>None of the trials reported on our remaining planned secondary mother or child outcomes:</p> <p> <ul id="CD003511-list-0014"> <li> <p>severity of 'morning sickness' ‐ intensified headache, nausea, breast tenderness;</p> </li> <li> <p>reported thromboembolic events;</p> </li> <li> <p>depression;</p> </li> <li> <p>admission to special care unit;</p> </li> <li> <p>subsequent fertility.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003511-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003511-sec-0124"></div> <section id="CD003511-sec-0125"> <h3 class="title" id="CD003511-sec-0125">Summary of main results</h3> <p>The aim of this review was to assess the effectiveness of progestogens to prevent recurrent miscarriage. There has been much speculation that progestogens may reduce the miscarriage recurrence rate, and the results of this meta‐analysis show that moderate‐quality evidence demonstrates that progestogen supplementation probably reduces the miscarriage rate for women with recurrent miscarriage. A subgroup analysis comparing placebo‐controlled versus non‐placebo‐controlled trials, trials of women with three or more prior miscarriages compared to women with two or more miscarriages and different routes of administration showed no clear differences between subgroups for miscarriage. </p> <p>The secondary outcome of live birth rate was also probably improved with progesterone therapy (moderate‐quality evidence). This is mainly driven by the primary outcome of reduced miscarriages, as the rates of stillbirth, if reported at all, were typically very low or zero. </p> <p>We are uncertain about the effect on the rate of preterm birth because the quality of this evidence is very low. It is clear from the literature about preventing preterm birth that progestogen therapy, vaginally or intramuscularly, can reduce preterm birth rates for some women (<a href="./references#CD003511-bbs2-0051" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>; <a href="./references#CD003511-bbs2-0061" title="KeirseMJ . Progestogen administration in pregnancy may prevent preterm delivery. British Journal of Obstetrics and Gynaecology1990;97(2):149‐54. ">Keirse 1990</a>). Thus, this finding should be interpreted with caution. Perhaps longer duration therapy in women with recurrent pregnancy loss may be warranted for future study. </p> <p>The meta‐analysis showed there may be little or no difference in stillbirths, neonatal death or the number of fetal abnormalities (including virilization and hypospadias) in babies whose mothers had been given progestogens whilst in utero. </p> <p>No trials reported any adverse maternal effects. There were many other planned secondary outcomes not reported. We may need to revise the outcome list for this topic and possibly unify it around a core set of outcomes for trials of miscarriage prevention. </p> </section> <section id="CD003511-sec-0126"> <h3 class="title" id="CD003511-sec-0126">Overall completeness and applicability of evidence</h3> <p>This updated review adds two recently published trials, which together strengthen the evidence that progestogen therapy probably reduces miscarriage rates for women with recurrent miscarriages. However, there are five trials that are ongoing or about to begin that may yet impact the evidence base, and so this conclusion may change in further updates of this review. </p> <p>As most of the included trials had different entry criteria and duration of therapy, determining a uniform protocol for treatment may be difficult. </p> </section> <section id="CD003511-sec-0127"> <h3 class="title" id="CD003511-sec-0127">Quality of the evidence</h3> <p>Overall, we judged most of the trials to be of low risk of bias for most of the categories. The majority of the trials were conducted before robust reporting of methods was instituted. For many of the older trials, generally for trials at the time the trials were performed, the overall quality appears to be reasonable. The more recent publications were generally of better quality with low risks of bias. This difference in reporting standards is commonly seen in reviews that include trials published before uniform reporting guidelines such as CONSORT were developed (<a href="./references#CD003511-bbs2-0072" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine2010;152:Epub 24 March. ">Schulz 2010</a>). </p> <p>Overall, the evidence ranged from very low to moderate the quality based on the GRADE system (<a href="./references#CD003511-bbs2-0073" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Available from gdt.gradepro.org/app/handbook/handbook.html. ">Schünemann 2013</a>). We assessed quality of evidence for the primary outcome of miscarriage and the main secondary outcomes of live birth rate and preterm birth. Limitations in study design led to downgrading of the evidence to moderate quality for the outcomes of miscarriage and live birth rate. Limitations in study design and very serious limitations in imprecision led to downgrading of the evidence to very low‐quality for the outcome preterm birth. </p> </section> <section id="CD003511-sec-0128"> <h3 class="title" id="CD003511-sec-0128">Potential biases in the review process</h3> <p>We took steps to minimize bias at every step of the review process: a comprehensive search of the literature was performed in order to identify all relevant studies and two authors independently assessed studies, performed data extraction and GRADE assessments. None of the review authors were involved in any of the included or excluded trials. We are unaware of any potential biases inherent in refocusing this update on women with recurrent pregnancies alone. The addition of a third review author in this update allowed for assessment and consensus around the study assessments. There was no funding provided for this review. </p> </section> <section id="CD003511-sec-0129"> <h3 class="title" id="CD003511-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p>Two other published systematic reviews agree with our findings. One review, <a href="./references#CD003511-bbs2-0048" title="CoomarasamyA , TruchanowiczEG , RaiR . Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages?. BMJ2011;342:d1914. ">Coomarasamy 2011</a>, included only four trials (all included in this updated review) and found benefit to progestogen. A more recent systematic review, <a href="./references#CD003511-bbs2-0071" title="SacconeG , SchoenC , FranasiakJM , ScottRTJr , BerghellaV . Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta‐analysis of randomized, controlled trials. Fertility and Sterility2017;107(2):430‐8. ">Saccone 2017</a>, included all trials included in this review. Thus, this updated Cochrane Review is in agreement with and includes more trials than prior published systematic reviews. A separate Cochrane Review has also been conducted on the use of progestogens for treating women with threatened miscarriage (<a href="./references#CD003511-bbs2-0078" title="WahabiHA , FayedAA , EsmaeilSA , BahkaliKH . Progestogen for treating threatened miscarriage. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD005943.pub5] ">Wahabi 2018</a>), and this also suggests a benefit in terms of a reduction in miscarriage in those women treated with progestogens. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003511-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1. Progestogen versus placebo/no treatment, outcome 1.1 Miscarriage (all trials)" data-id="CD003511-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison 1. Progestogen versus placebo/no treatment, outcome 1.1 Miscarriage (all trials) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD003511-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD003511-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003511-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 1 Miscarriage (all trials)." data-id="CD003511-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 1 Miscarriage (all trials).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 2 Miscarriage (placebo‐controlled trials only)." data-id="CD003511-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 2 Miscarriage (placebo‐controlled trials only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 3 Miscarriage (women with previous recurrent miscarriage only)." data-id="CD003511-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 3 Miscarriage (women with previous recurrent miscarriage only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 4 Miscarriage (by route of administration versus placebo)." data-id="CD003511-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 4 Miscarriage (by route of administration versus placebo). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 5 Live birth rate." data-id="CD003511-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 5 Live birth rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 6 Preterm birth." data-id="CD003511-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 6 Preterm birth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 7 Neonatal death." data-id="CD003511-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 7 Neonatal death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 8 Fetal genital abnormalities/virilization." data-id="CD003511-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 8 Fetal genital abnormalities/virilization.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 9 Stillbirth." data-id="CD003511-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 9 Stillbirth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003511-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/urn:x-wiley:14651858:media:CD003511:CD003511-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_t/tCD003511-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progestogen versus placebo/no treatment, Outcome 10 Low birthweight (&lt; 2500 g)." data-id="CD003511-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Progestogen versus placebo/no treatment, Outcome 10 Low birthweight (&lt; 2500 g). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/media/CDSR/CD003511/image_n/nCD003511-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003511-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Progestogen compared to placebo/no treatment for preventing miscarriage in women with recurrent miscarriage of unclear etiology</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Progestogen compared to placebo/no treatment for preventing miscarriage in women with recurrent miscarriage of unclear etiology</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with recurrent miscarriage of unclear etiology<br/> <b>Setting:</b> mix of multicenter and single‐center trials based in Egypt, India, Jordan, UK and USA </p> <p><b>Intervention:</b> progestogen<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo/no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Miscarriage</b> (all trials) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>average RR 0.73<br/> (0.54 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1684<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000<br/> (149 to 275) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Live birth rate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (1.00 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1411<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>701 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000<br/> (701 to 793) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Preterm birth</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.53 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>256<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/> (40 to 180) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded (1) level for serious limitations in study design due to some of the studies being at high or unclear risk for selection bias. </p> <p><sup>2</sup> We downgraded (2) levels for very serious limitations in imprecision due to small number of events, small sample size and wide CI crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Progestogen compared to placebo/no treatment for preventing miscarriage in women with recurrent miscarriage of unclear etiology</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/full#CD003511-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003511-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progestogen versus placebo/no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Miscarriage (all trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.54, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Miscarriage (placebo‐controlled trials only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.54, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Trials with placebo control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Trials without placebo controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.34, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Miscarriage (women with previous recurrent miscarriage only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Women with a history of 3 or more prior miscarriages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.34, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Women with a history of 2 or more prior miscarriages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.64, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Miscarriage (by route of administration versus placebo) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.51, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oral versus placebo/control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.39, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Intramuscular versus placebo/control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.30, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Vaginal versus placebo/control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.00, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Preterm birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.53, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.36, 8.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Fetal genital abnormalities/virilization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.07, 16.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Low birthweight (&lt; 2500 g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.36, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progestogen versus placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003511.pub5/references#CD003511-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003511.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003511-note-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003511-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003511-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD003511-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD003511-note-0002">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003511-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD003511-note-0013">Português</a> </li> <li class="section-language"> <a class="" href="th#CD003511-note-0001">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003511-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003511-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003511\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003511\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003511\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003511\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003511\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003511.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003511.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003511.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003511.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003511.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717584736"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003511.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717584740"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003511.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbb824fc79371',t:'MTc0MDcxNzU4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 